The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin

Recent studies are reviewed indicating that the transcription factor early growth response-1 (Egr1) is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin. The downstream pathways of these factors display multiple nodes of interaction with each other, suggesting the existence of a functional network of suppressor factors that serve to maintain normal growth regulation and resist the emergence of transformed variants. Paradoxically, Egr1 is oncogenic in prostate cancer. In the majority of these cancers, PTEN or p53 is inactive. It is suggested that these defects in the suppressor network allow for the unopposed induction of TGFβ1 and fibronectin, which favor transformation and survival of prostate tumor epithelial cells, and explain the role of Egr1 in prostate cancer. Egr1 is a novel and logical target for intervention by gene therapy methods, and targeting methods are discussed.

[1]  D. Mercola,et al.  Method for cloning in vivo targets of the Egr-1 transcription factor. , 2000, BioTechniques.

[2]  J. Milbrandt,et al.  Infertility associated with incomplete spermatogenic arrest and oligozoospermia in Egr4-deficient mice. , 1999, Development.

[3]  F. Cuttitta,et al.  Differential induction of early response genes by adrenomedullin and transforming growth factor-beta1 in human lung cancer cells. , 2002, Anticancer research.

[4]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.

[5]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[6]  E. Adamson,et al.  The phosphorylated forms of the transcription factor, Egr-1, bind to DNA more efficiently than non-phosphorylated. , 1994, Biochemical and biophysical research communications.

[7]  J. Milbrandt,et al.  Functional Compensation by Egr4 inEgr1-Dependent Luteinizing Hormone Regulation and Leydig Cell Steroidogenesis , 2000, Molecular and Cellular Biology.

[8]  C. Zarins,et al.  Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. , 2002, Experimental and molecular pathology.

[9]  Dan Mercola,et al.  Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Sakai,et al.  Molecular cloning and functional characterization of the upstream promoter region of the human p73 gene. , 1999, DNA research : an international journal for rapid publication of reports on genes and genomes.

[11]  E. Adamson,et al.  A biological role for Egr-1 in cell survival following ultra-violet irradiation. , 1995, Oncogene.

[12]  D. Mercola,et al.  EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. , 1996, Critical reviews in oncogenesis.

[13]  Tim Hui-Ming Huang,et al.  Oligonucleotide‐based microarray for DNA methylation analysis: Principles and applications , 2003, Journal of cellular biochemistry.

[14]  H. Baloglu,et al.  Tissue fibronectin levels of human prostatic cancer, as a tumor marker. , 1995, Cancer biochemistry biophysics.

[15]  T. Haneji,et al.  PTEN expression elicited by EGR‐1 transcription factor in calyculin A‐induced apoptotic cells , 2005, Journal of cellular biochemistry.

[16]  D. C. Han,et al.  High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. , 1999, Journal of the American Society of Nephrology : JASN.

[17]  U. Moll,et al.  p63 and p73: roles in development and tumor formation. , 2004, Molecular cancer research : MCR.

[18]  James M. Roberts,et al.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. , 1993, Science.

[19]  V. Rangnekar,et al.  EGR-1 Induction Is Required for Maximal Radiosensitivity in A375-C6 Melanoma Cells* , 1996, The Journal of Biological Chemistry.

[20]  Mark A. Watson,et al.  EGR1 Target Genes in Prostate Carcinoma Cells Identified by Microarray Analysis* , 2000, The Journal of Biological Chemistry.

[21]  M. Pignatelli,et al.  The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. , 2003, The Biochemical journal.

[22]  I. Larripa,et al.  Non-random distribution of spontaneous chromosome aberrations in two Bloom Syndrome patients. , 2004, Hereditas.

[23]  T. Maclachlan,et al.  Insights into differential endostatin activity , 2004, Cancer biology & therapy.

[24]  G. Tell,et al.  Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells. , 2004, Endocrinology.

[25]  P. Howe,et al.  TGF‐β induces fibronectin synthesis through a c‐Jun N‐terminal kinase‐dependent, Smad4‐independent pathway , 1999, The EMBO journal.

[26]  L. Chodosh,et al.  Conditional Overexpression of Active Transforming Growth Factor β1 In vivo Accelerates Metastases of Transgenic Mammary Tumors , 2004, Cancer Research.

[27]  H. Yamanaka,et al.  Potential role of HBGF (FGF) and TGF-beta on prostate growth. , 1992, Advances in experimental medicine and biology.

[28]  M. Hori,et al.  Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial α-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (UUO) rats , 2002, Gene Therapy.

[29]  K. Sekiguchi,et al.  Suppression of transformed phenotypes of human fibrosarcoma cells by overexpression of recombinant fibronectin. , 1996, Cancer research.

[30]  R. Weichselbaum,et al.  Molecular targeting of gene therapy and radiotherapy. , 2001, Acta oncologica.

[31]  M. Fu,et al.  Early stimulation and late inhibition of peroxisome proliferator-activated receptor gamma (PPAR gamma) gene expression by transforming growth factor beta in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads. , 2003, The Biochemical journal.

[32]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Mak,et al.  Physiological functions of Pten in mouse tissues. , 2003, Cell structure and function.

[34]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[35]  A. Balmain,et al.  Genetic events and the role of TGFβ in epithelial tumour progression , 1999 .

[36]  J. Fata,et al.  Insulin-like Growth Factor-II Regulates PTEN Expression in the Mammary Gland* , 2003, Journal of Biological Chemistry.

[37]  T. McDonnell,et al.  Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. , 1999, Seminars in oncology.

[38]  S. Frisch,et al.  Anoikis mechanisms. , 2001, Current opinion in cell biology.

[39]  Shunyou Wang,et al.  PTENless means more. , 2004, Developmental biology.

[40]  P. Humphrey,et al.  Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. , 2001, Human pathology.

[41]  O. Cussenot,et al.  Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. , 1999, Cytokine.

[42]  L. Languino,et al.  Regulation of β1C and β1A Integrin Expression in Prostate Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[43]  A. Woodard,et al.  Substrate Specificity of αvβ3Integrin-mediated Cell Migration and Phosphatidylinositol 3-Kinase/AKT Pathway Activation* , 2000, The Journal of Biological Chemistry.

[44]  M. Cybulsky,et al.  High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. , 2000, The Journal of clinical investigation.

[45]  Ruo-Pan Huang,et al.  p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis , 1999, Oncogene.

[46]  D. Mercola,et al.  Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Porcellini,et al.  Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma , 2004, Cancer Cell International.

[48]  H. S. Sharma,et al.  Angiotensin II Induces Hypertrophy of Human Airway Smooth Muscle Cells : Expression of Transcription Factors and Transforming Growth Factor-b 1 , 1998 .

[49]  Ruo-Pan Huang,et al.  Egr-1 inhibits apoptosis during the UV response: correlation of cell survival with Egr-1 phosphorylation , 1998, Cell Death and Differentiation.

[50]  Xiao-Fan Wang,et al.  Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.

[51]  D. Mercola,et al.  Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo , 2003, Oncogene.

[52]  C. Allegra,et al.  Physical interaction between p53 and primary response gene Egr-1. , 2001, International journal of oncology.

[53]  V. Rangnekar,et al.  Suppression of growth and transformation and induction of apoptosis by EGR-1. , 1998, Cancer gene therapy.

[54]  T. Sakai,et al.  Molecular Cloning and Functional Characterization of the Upstream Promoter Region of the Human p 73 Gene , 2007 .

[55]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[56]  R. Figlin,et al.  Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. , 1995, Oncogene.

[57]  V. Rangnekar,et al.  Early Growth Response-1-dependent Apoptosis Is Mediated by p53* , 1997, The Journal of Biological Chemistry.

[58]  Dan Mercola,et al.  Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. , 2005, Cancer research.

[59]  Gower,et al.  Fibronectin influences cellular proliferation and apoptosis similarly in LNCaP and PC-3 prostate cancer cell lines. , 2000, Urologic oncology.

[60]  D. Tindall,et al.  Expression of early growth response genes in human prostate cancer. , 1998, Cancer research.

[61]  R. Weichselbaum,et al.  Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. , 2004, Molecular cancer therapeutics.

[62]  D. Mercola,et al.  The Transcription Factor EGR-1 Directly Transactivates the Fibronectin Gene and Enhances Attachment of Human Glioblastoma Cell Line U251* , 2000, The Journal of Biological Chemistry.

[63]  L. Mayo,et al.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. , 2002, Trends in biochemical sciences.

[64]  K. Hashimoto,et al.  Regulation of constitutive expression of mouse PTEN by the 5′-untranslated region , 2003, Oncogene.

[65]  J. Rhim,et al.  Antisense to the Early Growth Response‐1 Gene (Egr‐1) Inhibits Prostate Tumor Development in TRAMP Mice , 2003, Annals of the New York Academy of Sciences.

[66]  B. Marples,et al.  Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin , 2005, Cancer Gene Therapy.

[67]  D. Mercola,et al.  Egr1 Promotes Growth and Survival of Prostate Cancer Cells , 2003, The Journal of Biological Chemistry.

[68]  G. Bepler,et al.  EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  P. Howe,et al.  Analysis of TGFβ-Mediated Synthesis of Extracellular Matrix Components , 2000 .

[70]  M. Gleave,et al.  Human prostate cancer model: Roles of growth factors and extracellular matrices , 1992, Journal of cellular biochemistry. Supplement.

[71]  S. Han,et al.  CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1. , 1999, International immunology.

[72]  M. Sporn,et al.  Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. , 1994, Molecular endocrinology.

[73]  C. Allegra,et al.  Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  A. Bernheim,et al.  Evolution of chromosomal alterations and biologic features in two small cell lung carcinoma cell lines established from one patient during the course of the disease. , 1995, Cancer genetics and cytogenetics.

[75]  S. Downing,et al.  Alterations of p53 are common in early stage prostate cancer. , 2003, The Canadian journal of urology.

[76]  J. Milbrandt,et al.  Early Growth Response Gene 1–mediated Apoptosis Is Essential for Transforming Growth Factor β1–induced Pulmonary Fibrosis , 2004, The Journal of experimental medicine.

[77]  J. Jacobberger,et al.  TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression. , 2000, Experimental Cell Research.

[78]  D. Mercola,et al.  Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation , 1997, International journal of cancer.

[79]  P. Howe,et al.  Analysis of TGF-beta-mediated synthesis of extracellular matrix components. , 2000, Methods in molecular biology.

[80]  Ruo-Pan Huang,et al.  The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor-β1, Fibronectin, and Plasminogen Activator Inhibitor-1* , 1999, The Journal of Biological Chemistry.

[81]  Xiao-Fan Wang,et al.  Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[82]  T. Mustelin,et al.  The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling , 2001, Nature Cell Biology.

[83]  M. Albrecht,et al.  Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance , 1999, Histochemistry and Cell Biology.

[84]  J. Jacobberger,et al.  TGF-β-Mediated Cell Cycle Arrest of HPV16-Immortalized Human Ectocervical Cells Correlates with Decreased E6/E7 mRNA and Increased p53 and p21WAF-1 Expression , 2000 .

[85]  J. Milbrandt,et al.  Luteinizing Hormone Deficiency and Female Infertility in Mice Lacking the Transcription Factor NGFI-A (Egr-1) , 1996, Science.

[86]  P. Humphrey,et al.  Impaired prostate tumorigenesis in Egr1-deficient mice , 2001, Nature Medicine.

[87]  E. Ruoslahti,et al.  Fibronectin and its integrin receptors in cancer. , 1999, Advances in cancer research.

[88]  Jin-Tang Dong.  Chromosomal Deletions and Tumor Suppressor Genes in Prostate Cancer , 2004, Cancer and Metastasis Reviews.

[89]  M. Dobbelstein,et al.  ΔNp73 can modulate the expression of various genes in a p53-independent fashion , 2003, Oncogene.

[90]  D. Mercola,et al.  Transformation-specific pattern of phosphorylation of c-Jun, Jun-B, Jun-D and Egr-1 in v-sis transformed cells. , 1994, Carcinogenesis.

[91]  M. Hashizume,et al.  Abnormal PTEN expression in portal hypertensive gastric mucosa: A key to impaired PI 3‐kinase/Akt activation and delayed injury healing? , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[92]  D. Russell,et al.  Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. , 1996, The Journal of urology.

[93]  O. Cussenot,et al.  UPREGULATION OF ENDOTHELIN 1 AND ITS PRECURSOR BY IL-1β, TNF-α, and TGF-β IN THE PC3 HUMAN PROSTATE CANCER CELL LINE , 1999 .

[94]  A. Porcellini,et al.  The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  A. Balmain,et al.  Genetic events and the role of TGF beta in epithelial tumour progression. , 1999, The Journal of pathology.